Brad Stevens Quotes

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

I want to make a drug. I want the science to be more than imaginary, where I think, 'We're learning these fundamental principles, blah, blah, blah, blah, blah.' I think we are doing that, but I want to do something really practical. I want to actually, in my lifetime, help people.

To start with, pharma was an industry based on innovation, drug discovery.

There's always going to be the need for new medications, better medications.

Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

I keep encouraging the pharmaceutical companies to put more money into R&D.

If you go to the FDA with a drug that's only meant to treat 50 people, and it's a 95 percent cure rate, you'll get your drug approved.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

Efforts to approach zero risk through exhaustive pre-release testing are extremely expensive and time-consuming. New drugs are delayed in reaching those who need them, and marginal drugs may not be developed at all.

There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.

The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.

If my drug Ragaglitazar had been successful, we would have been getting royalties of thousands of crore rupees every year.

We all want our drugs to be safe - and so an essential part of the pathway to the development of a new drug is approval by a regulator.

On the third stage is used for medicine, it is not known to the public.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

I think Trump's going to make it easier to be a drug company in America.

We should look for ways to expedite generic drug approvals, particularly for products that have a long history of being safe and effective.

I really was inspired by the possibility of more directly being involved in the development of drugs myself.

It's O.K. if you've got a smartphone app or a social network, and you go live with it before it's ready; people aren't going to die. But with medicine, it's different.

In contrast to how tech firms want to disrupt and break things - developing drugs must be incremental and step-by-step. This is the kind of work that involves people putting their lives on the line every day with clinical trials.

I agree, the world would be a better place if doctors were less enthusiastic about adopting very new drugs.

The public relies on the advice of doctors and leading researchers. The public has a right to know about financial relationships between those doctors and the drug companies who make the pharmaceuticals prescribed by doctors.

Medicines are unusual commodities. Important drugs can save the lives and protect the health of millions. Their consumption can bring huge benefits, by helping patients to avoid infection and preventing serious damage to the economies of families, nations and even humanity at large.